Compare TZOO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | VRCA |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 88.0M |
| IPO Year | 2003 | 2018 |
| Metric | TZOO | VRCA |
|---|---|---|
| Price | $6.75 | $5.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $17.50 | $17.00 |
| AVG Volume (30 Days) | 64.1K | ★ 82.4K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $9.52 | $94.44 |
| P/E Ratio | $222.00 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $4.72 | $3.28 |
| 52 Week High | $12.39 | $9.82 |
| Indicator | TZOO | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 47.63 |
| Support Level | $6.73 | $4.25 |
| Resistance Level | $7.31 | $6.67 |
| Average True Range (ATR) | 0.24 | 0.40 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 18.27 | 37.50 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.